A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Trial Profile

A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Vistusertib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 Dec 2017 Data from this trial will be presented at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition, according to an AstraZeneca media release.
    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top